Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Skin Soft Tissue Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Skin Neoplasm
Skin Soft Tissue Neoplasm

Cancer Family

Skin Soft Tissue Neoplasm

CI-CAN-00000352Explore in graph →

Non-malignant10 active trials9 evidence items

NCIt: C169100

Overview
Statistics
Survival
Genomics
Variants & evidence9
Drugs2
Trials36
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (7)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–7 of 7 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.
· Hum Pathol · 2008 · PMID 17950782 · validated civic_curation pubmed
Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays.
· Hum Pathol · 2011 · PMID 21111450 · validated civic_curation pubmed
Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans.
· Mod Pathol · 2007 · PMID 17431412 · validated civic_curation pubmed
Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.
· Br J Dermatol · 2022 · PMID 35441365 · validated civic_curation pubmed
A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.
· Onco Targets Ther · 2018 · PMID 29760553 · validated civic_curation pubmed
COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22).
· Cancer Genet Cytogenet · 2006 · PMID 16843106 · validated civic_curation pubmed
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Showing 1–7 of 7 publications

· Mol Cancer Ther · 2015 · PMID 25852058 · validated civic_curation pubmed